Ceshi Chen

10.2k total citations · 1 hit paper
182 papers, 6.8k citations indexed

About

Ceshi Chen is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Ceshi Chen has authored 182 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 147 papers in Molecular Biology, 60 papers in Oncology and 39 papers in Cancer Research. Recurrent topics in Ceshi Chen's work include Kruppel-like factors research (48 papers), Cancer-related gene regulation (37 papers) and Ubiquitin and proteasome pathways (33 papers). Ceshi Chen is often cited by papers focused on Kruppel-like factors research (48 papers), Cancer-related gene regulation (37 papers) and Ubiquitin and proteasome pathways (33 papers). Ceshi Chen collaborates with scholars based in China, United States and Hong Kong. Ceshi Chen's co-authors include Jin‐Tang Dong, Zhongmei Zhou, Rong Liu, Xu Zhi, Lydia E. Matesic, Xiaodong Sun, Jiao Wu, Chao Dong, Robert L. Vessella and Wenlin Chen and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Ceshi Chen

176 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

2021 256 citations Jian‐Yun Nie, Ceshi Chen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ceshi Chen China	49	5.2k	1.6k	1.6k	915	656	182	6.8k
Rakesh Kumar United States	47	4.6k 0.9×	2.2k 1.4×	1.2k 0.8×	1.7k 1.8×	816 1.2×	160	7.1k
Roseline Godbout Canada	44	4.9k 0.9×	1.7k 1.1×	1.5k 0.9×	1.1k 1.2×	439 0.7×	132	6.9k
Eugenio Santos Spain	45	5.8k 1.1×	2.2k 1.3×	1.1k 0.7×	1.0k 1.1×	873 1.3×	154	8.3k
Guangchao Sui United States	35	4.6k 0.9×	862 0.5×	1.2k 0.8×	705 0.8×	346 0.5×	94	6.5k
Masatoshi Kitagawa Japan	46	5.9k 1.1×	2.7k 1.7×	1.8k 1.2×	575 0.6×	1.0k 1.5×	144	7.8k
Karen Blyth United Kingdom	43	4.7k 0.9×	1.9k 1.2×	2.2k 1.4×	385 0.4×	630 1.0×	134	7.0k
Shigeo Sato Japan	41	4.4k 0.8×	1.9k 1.2×	1.0k 0.7×	453 0.5×	522 0.8×	71	6.4k
Asha S. Multani United States	40	5.0k 1.0×	3.3k 2.0×	1.9k 1.2×	691 0.8×	677 1.0×	126	8.2k
Dung‐Fang Lee United States	36	4.9k 0.9×	1.6k 1.0×	1.4k 0.9×	368 0.4×	416 0.6×	87	6.3k
Gen Sheng Wu United States	47	5.0k 1.0×	2.1k 1.3×	1.4k 0.9×	567 0.6×	498 0.8×	87	6.6k

Countries citing papers authored by Ceshi Chen

Since Specialization

Citations

This map shows the geographic impact of Ceshi Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ceshi Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ceshi Chen more than expected).

Fields of papers citing papers by Ceshi Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ceshi Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ceshi Chen. The network helps show where Ceshi Chen may publish in the future.

Co-authorship network of co-authors of Ceshi Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Ceshi Chen. A scholar is included among the top collaborators of Ceshi Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ceshi Chen. Ceshi Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lu, Hua, Yao Liu, Jiabei Wang, et al.. (2025). Micropeptide hSPAR regulates glutamine levels and suppresses mammary tumor growth via a TRIM21-P27KIP1-mTOR axis. The EMBO Journal. 44(5). 1414–1441. 3 indexed citations

Zhang, Kevin Y., Yufei He, Li Li, et al.. (2025). Self-enriching nanozyme with photothermal-cascade amplification for tumor microenvironment-responsive synergistic therapy and enhanced photoacoustic imaging. Materials Today Bio. 34. 102230–102230. 1 indexed citations

Zhou, Jinge, Ziyu Zhou, Zhehao Wang, et al.. (2024). Lipid nanoparticles produce chimeric antigen receptor macrophages (CAR-M) in situ for the treatment of solid tumors. Nano Today. 61. 102610–102610. 3 indexed citations

Ren, Wenlong, Huichun Liang, Jian Sun, et al.. (2024). TNFAIP2 promotes HIF1α transcription and breast cancer angiogenesis by activating the Rac1-ERK-AP1 signaling axis. Cell Death and Disease. 15(11). 821–821. 3 indexed citations

Kong, Yanjie, Tianlong Lan, Gong Chen, et al.. (2024). BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression. Oncogene. 43(39). 2914–2926. 8 indexed citations

Fang, Huan, Huichun Liang, Chuanyu Yang, et al.. (2024). STAMBPL1 activates the GRHL3/HIF1A/VEGFA axis through interaction with FOXO1 to promote angiogenesis in triple-negative breast cancer. eLife. 13.

Li, Wei, Chuanyu Yang, Zhuo Cheng, et al.. (2024). Gallium complex K6 inhibits colorectal cancer by increasing ROS levels to induce DNA damage and enhance phosphatase and tensin homolog activity. SHILAP Revista de lepidopterología. 5(8). e665–e665. 1 indexed citations

Zhang, Lixing, Juchuanli Tu, Siqin Li, et al.. (2024). IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. Cancer Research. 84(14). 2282–2296. 26 indexed citations

Liu, Wenjing, Peng He, Yuzhan Li, et al.. (2023). Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. 66(11). 7421–7437. 4 indexed citations

10.

Hu, Zaoxiu, Ceshi Chen, Ting Chen, et al.. (2023). Low‐dose aspirin can inhibit exosomal release induced by radiotherapy in breast cancer and attenuate its inhibitory effect on NK cell proliferation. Cancer Medicine. 12(15). 16386–16404. 9 indexed citations

11.

Wang, Han, Chenglin Liu, Yi Xiao, et al.. (2023). Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer. JNCI Journal of the National Cancer Institute. 115(12). 1586–1596. 6 indexed citations

12.

Zhou, Sihan, Wenhui Liao, Wei Li, et al.. (2023). (8-Hydroxyquinoline) Gallium(III) Complex with High Antineoplastic Efficacy for Treating Colon Cancer via Multiple Mechanisms. ACS Omega. 8(7). 6945–6958. 15 indexed citations

13.

Wang, Hui, Haibo Xu, Wei Chen, et al.. (2022). Rab13 Sustains Breast Cancer Stem Cells by Supporting Tumor–Stroma Cross-talk. Cancer Research. 82(11). 2124–2140. 17 indexed citations

14.

Li, Zhen, Ji Zhang, Wei Zou, et al.. (2021). The methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism is associated with breast cancer subtype susceptibility in southwestern China. PLoS ONE. 16(7). e0254267–e0254267. 6 indexed citations

15.

Liu, Yating, Chao Mao, Min Wang, et al.. (2020). Cancer progression is mediated by proline catabolism in non-small cell lung cancer. Oncogene. 39(11). 2358–2376. 60 indexed citations

16.

He, Lingli, Liang Yuan, Yang Sun, et al.. (2019). Glucocorticoid Receptor Signaling Activates TEAD4 to Promote Breast Cancer Progression. Cancer Research. 79(17). 4399–4411. 82 indexed citations

17.

Yang, Xiaosong, Pan You, Zhaojun Qiu, et al.. (2018). RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clinical Cancer Research. 24(7). 1629–1643. 30 indexed citations

18.

Wu, Jing, Ye Ding, Zhongmei Zhou, et al.. (2016). A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5. Cancer Letters. 380(2). 393–402. 51 indexed citations

19.

Xu, Lin, Bin Liang, Longbao Lü, et al.. (2013). Tree shrews under the spot light: emerging model of human diseases. Zoological Research. 34(2). 59–59. 38 indexed citations

20.

Zhi, Xu, Dong Zhao, Zehua Wang, et al.. (2012). E3 Ubiquitin Ligase RNF126 Promotes Cancer Cell Proliferation by Targeting the Tumor Suppressor p21 for Ubiquitin-Mediated Degradation. Cancer Research. 73(1). 385–394. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact